Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Hematology Division, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Blood. 2023 Dec 28;142(26):2258-2267. doi: 10.1182/blood.2023020081.
Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the expected survival can vary from a few months to >10 years. For the past 5 decades, patients with MDS have been classified into higher-risk vs lower-risk disease phenotypes using sequentially developed clinical prognostic scoring systems. Factors such as morphologic dysplasia, clinical hematologic parameters, cytogenetics, and, more recently, mutational information have been captured in prognostic scoring systems that refine risk stratification and guide therapeutic management in patients with MDS. This review describes the progressive evolution and improvement of these systems which has led to the current Molecular International Prognostic Scoring System.
风险分层和预后预测对于骨髓增生异常综合征（MDS）或骨髓增生性肿瘤患者的适当管理至关重要，这些患者的预期生存时间可从数月到>10 年不等。在过去的 50 年中，MDS 患者使用逐步开发的临床预后评分系统分为高风险与低风险疾病表型。预后评分系统中纳入了形态学发育不良、临床血液学参数、细胞遗传学以及最近的突变信息等因素，这些因素可对风险分层进行细化，并指导 MDS 患者的治疗管理。本综述描述了这些系统的不断发展和改进，从而导致了目前的分子国际预后评分系统的产生。
